A detailed history of Met Life Investment Management, LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 16,315 shares of FULC stock, worth $48,781. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,315
Previous 15,898 2.62%
Holding current value
$48,781
Previous $98,000 40.82%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.18 - $9.74 $1,326 - $4,061
417 Added 2.62%
16,315 $58,000
Q2 2024

Aug 13, 2024

BUY
$5.98 - $9.31 $95,070 - $148,010
15,898 New
15,898 $98,000
Q1 2023

May 09, 2024

BUY
$2.83 - $13.99 $78,359 - $387,369
27,689 New
27,689 $78.9 Million
Q1 2023

May 15, 2023

BUY
$2.83 - $13.99 $24,901 - $123,098
8,799 Added 46.58%
27,689 $78,000
Q4 2022

Jun 14, 2023

SELL
$5.01 - $8.35 $44,082 - $73,471
-8,799 Reduced 31.78%
18,890 $137,000
Q3 2022

May 10, 2024

BUY
$4.92 - $9.1 $19,133 - $35,389
3,889 Added 25.92%
18,890 $150,000
Q3 2022

Jun 14, 2023

SELL
$4.92 - $9.1 $43,291 - $80,070
-8,799 Reduced 31.78%
18,890 $150,000
Q3 2022

Mar 22, 2023

BUY
$4.92 - $9.1 $19,133 - $35,389
3,889 Added 25.92%
18,890 $150,000
Q3 2022

Nov 14, 2022

BUY
$4.92 - $9.1 $92,938 - $171,899
18,890 New
18,890 $153,000
Q2 2022

Aug 11, 2022

SELL
$4.2 - $24.0 $63,004 - $360,024
-15,001 Closed
0 $0
Q1 2022

May 10, 2024

BUY
$9.96 - $23.65 $149,409 - $354,773
15,001 New
15,001 $354,000
Q1 2022

Jun 20, 2023

SELL
$9.96 - $23.65 $126,372 - $300,071
-12,688 Reduced 45.82%
15,001 $354,000
Q1 2022

Mar 22, 2023

BUY
$9.96 - $23.65 $54,242 - $128,797
5,446 Added 57.0%
15,001 $354,000
Q1 2022

May 12, 2022

BUY
$9.96 - $23.65 $54,242 - $128,797
5,446 Added 57.0%
15,001 $355,000
Q4 2021

Jun 21, 2023

SELL
$14.0 - $28.44 $253,876 - $515,730
-18,134 Reduced 65.49%
9,555 $169,000
Q3 2021

May 17, 2024

BUY
$7.28 - $30.97 $69,560 - $295,918
9,555 New
9,555 $269,000
Q3 2021

Jun 21, 2023

SELL
$7.28 - $30.97 $132,015 - $561,609
-18,134 Reduced 65.49%
9,555 $269,000
Q3 2021

Mar 22, 2023

BUY
$7.28 - $30.97 $23,936 - $101,829
3,288 Added 52.47%
9,555 $269,000
Q3 2021

Nov 15, 2021

BUY
$7.28 - $30.97 $69,560 - $295,918
9,555 New
9,555 $270,000
Q3 2020

Nov 13, 2020

SELL
$7.22 - $20.7 $45,247 - $129,726
-6,267 Closed
0 $0
Q2 2020

May 24, 2024

BUY
$9.11 - $22.06 $57,092 - $138,250
6,267 New
6,267 $115 Million
Q2 2020

Jun 26, 2023

SELL
$9.11 - $22.06 $195,154 - $472,569
-21,422 Reduced 77.37%
6,267 $114,000
Q2 2020

Mar 22, 2023

SELL
$9.11 - $22.06 $114,995 - $278,463
-12,623 Reduced 66.82%
6,267 $114,000
Q2 2020

Aug 14, 2020

BUY
$9.11 - $22.06 $57,092 - $138,250
6,267 New
6,267 $115,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $156M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.